ALVO vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALVO's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates weak financial health, with poor profitability, negative operating margins, and erratic earnings. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given negative operating margins and a low quick ratio of 0.54. Despite a modest 10.6% YoY revenue growth and a 55.59% gross margin, the company exhibits severe earnings instability, with a -161.1% YoY EPS decline and multiple quarters of massive negative surprises. The stock trades at a premium to its intrinsic value of $1.61, suggesting overvaluation based on current fundamentals. Analysts' target price of $18.83 appears disconnected from current performance and financial health.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALVO vs LLY: Head-to-Head Comparison
This page compares Alvotech (ALVO) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.